维普期刊资源整合服务平台（V6.5）

20篇 您的检索式：作者名="ROODHART JM"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

	题名	作者	年代	出处	被引量
1	The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway显示文摘	Roodhart JM Langenberg MH Witteveen E	2008	Current Clinical Pharmacology2008，3，2：	1
2	The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway显示文摘	Roodhart JM Langenberg MH Witteveen E	2008	Curr Clin Pharmacol2008，3，：	1
3	Rapid chemotherapyinduced acute endothelial progenitor cell mobilization:implications for antiangiogenic drugs as chemosensitizing agents显示文摘	Shaked Y Henke E Roodhart JM		0，，03：	1
4	Rapid chemotherapy-induced acute endothelial progenitor cell mobilization:implications for antiangiogenic drugs as chemosensitizing agents显示文摘	Shaked Y Henke E Roodhart JM		0，，03：	1
5	Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents 显示文摘	Shaked Y Henke E Roodhart JM	2008	Cancer Cell2008，14，3：	1
6	Vascular disrupting agents (VDAs) in anticancer therapy 显示文摘	Daenen LG Roodhart JM Shaked Y	2010	Curt Clin Pharmacol2010，5，3：	1
7	Analysis of docetaxeltherapy in elderly (為 70 years) castration resistant prostate cancer patientsenrolled in the Netherlands Prostate Study 显示文摘	Gerritse FL Meulenbeld HJ Roodhart JM	2013	Eur J Cancer2013，49，15：	1
8	Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients显示文摘	Roodhart JM Langenberg MH Vermaat JS	2010	Neoplasia2010，12，1：	1
9	The role of mesenchymal stem ceils in anti-cancer drug resistance and tumour progression显示文摘	Houthuijzen JM Daenen LG Roodhart JM	2012	Br J Cancer2012，106，：	1
10	Translating pre- clinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back显示文摘	Roodhart JM Langenberg MH Daenen LG	2009	Biochim Biophys Acta2009，1，：	1
11	Phase I evaluation of telatinib, a vascular endothelial growth factor recptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors显示文摘	LANGENBERG MH WITFEVEEN PO ROODHART JM	2010	Clin Cancer Res2010，16，7：	1
12	Target practice: lessons from phase Ill trials with bevacizumab and vatalanib in the treatment of advanced eolorectal cancer显示文摘	Los M Roodhart JM Voest EE	2007	Oncologist2007，12，4：	1
13	Mesenchymal stem cells induce resisitance to chemotherapy through the release of platinum-in- duced fatty acids显示文摘	Roodhart JM Daenen LG Stiqter EC	2011	Cancer Cell2011，20，3：	1
14	The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway显示文摘	Roodhart JM Langenberg MH Witteveen E	2008	Curr Clin Pharma- col2008，3，2：	1
15	The molecular basis of class side effects due to treatment with in- hibitors of the VEGF/VEGFR pathway显示文摘	ROODHART JM LANGENBERG MH WITTEVEEN E	2008	Curr Clin Pharma- col2008，3，2：	1
16	The role ofmesenchymal stem cells in anti -cancer drug resistance andtumour progression 显示文摘	Houthuijzen JM Daenen L G Roodhart JM	1901	Br J Cancer1901，106，19：	1
17	The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression显示文摘	Houthuijzen JM Daenen LG Roodhart JM	2012	Br J Cancer2012，106，12：	1
18	The molecularbasis of class side effects due to treatment with inhibitors of theVEGF/VEGFR pathway显示文摘	Roodhart JM Langenberg MH Witteveen E	2008	Curr Clin Pharmacol2008，3，2：	1
19	Target practice: lessons from phase Ⅲ trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer显示文摘	Los M Roodhart JM Voest EE	2007	The Oncologist2007，12，4：	1
20	The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway显示文摘	Roodhart JM Langenberg MH Witteveen E	2008	Curr Clin Pharmacol2008，3，2：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示